Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years.

Key Points

• This study aims to evaluate the immunogenicity and safety of the RSV vaccine in younger adults at risk compared to older adults.
• Comparison of immune responses in adults aged 18-49 with underlying conditions and adults aged ≥60 years.
• Assessment of safety profiles post-vaccination.
• Monitoring immune responses up to 6 months post-vaccination.
• The vaccine showed noninferior immunogenicity in younger adults compared to older adults.
• Robust immune responses were observed in the younger cohort.
• The safety profile of the vaccine was deemed acceptable.